Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 4Active not recruiting 3Recruiting 2Withdrawn 1Unknown 1Terminated 1Available 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 4Sarcoma 2Leukemia, Myeloid, Acute 2Thymoma 1Recurrence 1Rectal Neoplasms 1Neoplasm Metastasis 1Lymphoma, T-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Drug-Related Side Effects and Adverse Reactions 1

Interventions

Rituximab 57Cyclophosphamide 40Vincristine 26Prednisone 25Doxorubicin 22Cytarabine 18Lenalidomide 17Etoposide 17Gemcitabine 12Melphalan 8Filgrastim 8Cisplatin 8zanubrutinib 7Peripheral Blood Stem Cell Transplantation 7Oxaliplatin 7N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 7Methotrexate 7Ifosfamide 7Carmustine 7R-CHOP protocol 6fludarabine phosphate 5Vindesine 5Radiotherapy 5Dexamethasone 5Decitabine 5Busulfan 5ibrutinib 4Methylprednisolone 4Epirubicin 4Cyclosporine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Lymphoma, Large B-Cell, Diffuse × selinexor × Clear all
NCT05786989 2023-03-28

Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma

Chongqing University Cancer Hospital

Phase 4 Unknown
32 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡